Periprosthetic Joint Infection (PJI)
Medicare spends more on total joint replacement than any other surgical procedure. Periprosthetic joint infection (PJI) is the most common and most costly cause of failure of these procedures. Over 58,000 PJIs are estimated to occur in the US this year, a number that has tripled in the last 20 years. With a single PJI costing $100,000 or more to treat, this represents a multibillion dollar burden on the healthcare system.
The current standard of care for PJI is a two-stage treatment process. Stage 1 is removal of all implants and infected tissue, then insertion of an antibiotic-loaded bone cement (ALBC) “spacer” for local high level antibiotic delivery. The spacer also provides temporary load bearing, but it must be removed eventually. Stage 2 is a second surgery once the initial infection is cleared, in which the spacer is removed and the joint is reconstructed with a new implant.
SBG002 may enable effective treatment of PJI in a single surgery by providing effective local antimicrobial delivery sufficient to kill any remaining bacteria, including those in biofilm, while being compatible with insertion of a permanent implant. This would enable a new standard of care, eliminating the additional morbidity and cost of the second stage.